Trends in incidence, prevalence, and mortality of neuromuscular disease in Ontario, Canada: A population-based retrospective cohort study (2003-2014)

Louise Rose, Douglas McKim, David Leasa, Mika Nonoyama, Anu Tandon, Yu Qing Bai, Reshma Amin, Sherri Katz, Roger Goldstein, Andrea Gershon

1 Department of Critical Care, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, Canada, 2 Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King’s College London, London, United Kingdom, 3 Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada, 4 Institute of Clinical Evaluative Sciences, Toronto, Canada, 5 The Ottawa Hospital Respiratory Rehabilitation and The Ottawa Hospital Sleep Centre and Ottawa Hospital Research Institute, Ottawa, Canada, 6 Faculty of Medicine, University of Ottawa, Ottawa, Canada, 7 Department of Medicine, Divisions of Critical Care and Respiratory, London Health Sciences Centre, London, Canada, 8 Faculty of Medicine, Western University, London, Canada, 9 Faculty of Health Sciences, University of Ontario Institute of Technology, Oshawa, Canada, 10 Hospital for Sick Children (SickKids) Research Institute, Toronto, Canada, 11 Rehabilitation Sciences Institute, University of Toronto, Toronto, Canada, 12 Department of Respirology & Clinical Immunology, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, Canada, 13 Faculty of Medicine, University of Toronto, Toronto, Canada, 14 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada, 15 Children’s Hospital of Eastern Ontario and Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada, 16 West Park Healthcare Centre, Toronto, Canada

* louise.rose@utoronto.ca

Abstract

Background

Population trends of disease prevalence and incidence over time measure burden of disease and inform healthcare planning. Neuromuscular disorders (NMD) affect muscle and nerve function with varying degrees of severity and disease progression.

Objective

Using health administrative databases we described trends in incidence, prevalence, and mortality of adults and children with NMD. We also explored place of death and use of palliative care.

Methods

Population-based (Ontario, Canada) cohort study (2003 to 2014) of adults and children with NMD identified using International Classification of Disease and health insurance billing codes within administrative health databases.
Results

Adult disease prevalence increased on average per year by 8% (95% confidence interval (CI) 6% to 10%, P < .001), with the largest increase in adults 18-39 years. Childhood disease prevalence increased by 10% (95% CI 8% to 11%, P < .0001) per year, with the largest increase in children 0 to 5 years. Prevalence increased across all diagnoses except amyotrophic lateral sclerosis and spinal muscular atrophy for adults and all diagnoses for children. Adult incidence decreased by 3% (95% CI -4% to -2%, P < .0001) but incidence remained stable in children. Death occurred in 34,336 (18.5%) adults; 21,236 (61.8%) of whom received palliative care. Death occurred in 1,009 (5.6%) children; 507 (50.2%) of whom received palliative care. Mortality decreased over time in adults (odds ratio (OR) 0.86, 95% CI 0.86–0.87, P < .0001) and children (OR 0.79, 95% CI 0.76–0.82, P < .0001). Use of palliative care over time increased for adults (OR 1.18, 95% CI 1.09 to 1.28, P < .0001) and children (OR 1.22, 95% CI 1.20 to 1.23, P < .0001).

Conclusions

In both adults and children, NMD prevalence is rising and mortality rates are declining. In adults incidence is decreasing while in children it remains stable. This confirms on a population-based level the increased survival of children and adults with NMD.

Introduction

Neuromuscular disorders (NMD) vary in severity and disease progression [1, 2]. These disorders result in longstanding functional deficits that result in substantial utilization of healthcare resources in addition to the emotional, financial and social burden to those affected individuals and their families. Some forms of NMD are hereditary and manifest at birth or early childhood whereas the incidence of other forms increases with age [3]. On an international level, an aging population means the prevalence of NMD is likely to increase.

Although some estimates of NMD prevalence exist [4, 5], case ascertainment methods are highly variable and frequently biased. These include chart reviews, surveys, family histories, interviews with relatives and patient registries [4]. Few studies are conducted using population based health administration databases containing all publicly funded healthcare encounters for a region or an entire country. Population based estimates of disease prevalence and trends over time inform an understanding of the natural history as well as the impact of newer management interventions on the epidemiology of disease measure burden of disease and inform healthcare planning [6].

Understanding the magnitude of NMD at a population level is important to understand the impact on the healthcare system and the healthcare burden of individuals to inform healthcare policy. Therefore, we conducted a population based cohort study using health administrative databases to determine the prevalence, incidence, and mortality for adults and children with NMD. Our secondary objectives were to describe prevalence and incidence for various types of NMD, location of death, and use of palliative care services.
Methods

Study design

We conducted a retrospective population-based study using health administrative databases for the province of Ontario, Canada held at the Institute for Clinical Evaluative Sciences (ICES) using unique encoded identifiers to link databases. These databases contain anonymized data for all residents of the province of Ontario, population approximately 13 million [7]. In Canada, universal public health insurance funded through general taxation covers cost of all medically necessary care.

Population and data sources

From the Ontario Registered Persons Database (RPDB) we identified adults aged 18 to 105 and children aged 0 to <18 years with NMD using hospital diagnostic codes (International Classification of Disease (ICD)-9, ICD-10) or physician billing (Ontario Health Insurance Plan (OHIP)) codes a priori considered specific to NMD within health administration databases. We verified physician billing codes for NMD with neurologists working with research team members. We sought the first instance (from fiscal year 2003 onwards) of these codes considered the ‘most responsible’ or secondary contributing diagnoses indicating hospital admission with a NMD diagnosis in the Discharge Abstract Database. This database includes all hospitalizations including demographic, procedural data (up to 24 comorbidities and procedures), and in-hospital death [8]. We also examined hospital diagnostic codes in the National Ambulatory Care Reporting System containing all emergency department visits and physician billings codes in the OHIP database [9] that contains all physician billings including procedures (Fig 1). To establish death outside of hospital we linked to the RPDB. To determine use of palliative care we sought validated palliative care codes [10] in the the hospitalization, ambulatory care and physician databases as well as the Continuing Care Reporting System, the Complex Continuing Care database, and the Home Care Database.

For individuals with the first occurrence of a NMD diagnostic code found using a physician billing code, we sought to confirm NMD diagnosis by looking backwards and forwards in time (1998–2014) in the hospitalization database for a NMD-related hospital admission identified through an ICD code. For individuals identified using the physician billing code 349 which is used as a non-specific catch all code for NMD, we again looked backwards and forwards in the hospitalization (1998–2014) and ambulatory care (2000–2014) databases and sought ICD codes and physician billings from a neurologist or for an electromyogram to increase our certainty the patient had NMD.

We grouped hospital diagnostic and physician NMD billing codes into 12 categories: amyotrophic lateral sclerosis/motor neurone disease; cerebral palsy [11]; Guillain-Barré syndrome [12]; metabolic disorders; multiple sclerosis [13]; muscular dystrophy; myasthenia gravis [14]; neuromuscular disorders (non-specific diagnoses); neuropathy; post-polio syndrome; spina bifida; and spinal muscular atrophy. Wherever possible, we used codes previously reported in studies specific to these disease categories (see S1 File for disease specific codes).

Outcomes

We established annual prevalence and annual incidence considering all adults and all children with a NMD diagnosis, and separately for those adults and children identified through hospitalization or ED presentation during that year. We also established annual prevalence and incidence for each NMD disease category. However, due to inability to classify disease type further with identification of NMD using physician billing we restricted our estimates of prevalence...
and incidence to those individuals with case ascertainment through hospital and ED diagnostic (ICD) codes. To establish incidence, we used a five-year look back window to confirm the individual had not received any health services for NMD previously and calculated annual incidence from 1st April 2008 to 31st March 2015. Individuals with prior health services utilization for NMD in these years were counted as prevalent but not incident. We established all-cause mortality rates, identified death location (in or outside a hospital), and determined use of palliative care.

**Ethical considerations**

We conducted our study according to a pre-specified protocol approved by the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Ontario and according to privacy regulations of the Institute for Clinical Evaluative Sciences.

**Statistical analyses**

We estimated annual prevalence by dividing the number of affected individuals alive at the end of each fiscal year by the census population estimated in the corresponding year from the RPDB. To estimate annual incidence we divided the number of new cases by the number of individuals at risk for NMD, considered as all adults resident in the province of Ontario without NMD, also from the RPDB estimated census population. Using patient level data we examined linear trends of prevalence and incidence (overall and by age and sex categories) over time using linear regression models with year as an independent variable [15]. We examined
trends in mortality and proportion of adults and children receiving palliative care using logistic regression. We conducted analyses in SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA).

Results

Prevalence

For adults, the crude prevalence of NMD considering only those identified through an ED presentation or hospital admission averaged over the 12-year period (Fiscal years 2003–2014) was 72.6/100,000 adults whereas it was 1,344/100,000 adults when including those identified through physician billing (See Table A in S1 File for total eligible patient population and NMD prevalent cases). Prevalence of patients identified through ED presentation or hospital admission increased on average per year by 8% (95% CI 6% to 10%, P < .0001 for linear trend). Prevalence increased across all diagnoses except ALS and SMA (Table 1). Although prevalence was highest in adults aged ≥ 65 years and increased for all adult age categories, the greatest average increase was in younger adults: 18–39 years 11% per year (95% CI 10% to 11%) P < .0001; 40–64 8% per year (95% CI 7% to 9%) P < .0001 and in adults aged ≥ 65 years 4% per year (95% CI 2% to 5%, P < .0001) (Fig 2). Prevalence increased by 8% (95% CI 7% to 8%) in both males and females (Table B in S1 File).

For children, crude prevalence of NMD over the 12-year period (fiscal years 2003–2014) was 50.0/100,000 children considering only those identified through ED presentation or hospital admission whereas it was 544/100,000 children when also including those identified through physician billing. Prevalence increased on average per year by 10% (95% CI 8% to 11%, P < .0001 linear trend). Prevalence increased across all diagnoses (Table 1). Prevalence increased for all child age categories, though greatest average increase was in the youngest category: 0 to 5 years 11% per year (95% CI 11% to 12%) P < .0001; 6 to 10 6% per year (95% CI 5% to 7%) P < .0001 and aged 11 to 17 10% per year (95% CI 9% to 10%) P < .0001 (Fig 2). Prevalence increased slightly more in girls, 10% (95% CI 9% to 10%) than boys, 9% (95% CI 9% to 10%) (Table B in S1 File).

Incidence

For adults, the overall incidence of NMD over the 7-year period (2008–2014) was 10.6/100,000 adults considering only those identified through ED presentation or hospital admission and 182/100,000 adults when including those identified through physician billing. Incidence decreased on average per year by 3% (95% CI -4% to -2%, P < .0001 for linear trend). Incidence decreased over time for multiple sclerosis, Guillain Barré syndrome, cerebral palsy, post-polio syndrome and SMA (Table 2). Incidence did not change in adults aged 18–39 (-1%, 95% CI -3%, 2%, P = 0.45) but decreased in adults aged 40–64 (-5%, 95% CI -6% to -3%, P < 0.001) and in adults aged 65 and over (-6%, 95% CI -7% to -4%, P < 0.001) (Fig 3). Incidence decreased by 3% (95% CI -4% to -2%) in females and by 4% (95% CI -4% to -5%) in males (Table C in S1 File).

For children, incidence of NMD over the 7-year period (fiscal years 2008–2014) was 4.7/100,000 children considering only those identified through ED presentation or hospital admission and 56/100,000 including children identified through physician billing. Incidence remained relatively static overall (2%, 95% CI -7% to 2%, P = 0.169 linear trend) and across all age categories (Fig 3). Incidence decreased over time for multiple sclerosis, neuropathies, and myasthenia gravis (Table 2). Incidence decreased by 7% (95% CI -9% to -4%) in males but remained unchanged in females (Table C in S1 File).
Mortality and use of palliative care

Of adults with NMD identified through hospitalization or ED presentation, 34,336 (18.5%) died over the 12-year period (16,458 (47.9%) in hospital), of whom 21,236 (61.8%) received palliative care. The proportion of individuals with NMD who died decreased from 34.8% in 2003 to 24% in 2014 (odds ratio (OR) 0.86 95% CI 0.86 to 0.87, P <.0001 for linear trend). At the same time, use of palliative care increased on average from 9.9% in 2003 to 21.5% in 2014 (OR 1.18, 95% CI 1.09 to 1.28, P <.0001 for linear trend).

Of children with NMD, 1,009 (5.6%) died over the 12 year period (482 (47.8%) in hospital), of whom 507 (50.2%) received palliative care. The proportion of children that died decreased from 7.9% in 2003 to 3% in 2014 (OR 0.79 95% CI 0.76 to 0.82%, P <.0001 linear trend). At the same time, use of palliative care increased (OR 1.22, 95% CI 1.20 to 1.23, P <.0001 linear trend).

Table 1. Prevalence by year.

| Overall (yrs) | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | Rateb | 95% CI | P< |
|-------------|------|------|------|------|------|------|------|------|------|------|------|------|-------|------|-----|
| Adults      |      |      |      |      |      |      |      |      |      |      |      |      |       |      |    |
| All NMD diagnoses | 72.7 | 30.3 | 43.9 | 53.7 | 62.2 | 68.6 | 74.4 | 78.9 | 84.4 | 88.7 | 92.7 | 95.4 | 98.7  | 0.08 | <.0001 |
| Multiple sclerosis | 18.8 | 9.4  | 12.7 | 14.7 | 16.4 | 17.9 | 19.2 | 20.0 | 21.1 | 21.9 | 23.0 | 24.0 | 24.9  | 0.07 | <.0001 |
| Cerebral palsy | 9.8  | 3.9  | 6.0  | 7.4  | 8.7  | 9.6  | 10.4 | 10.9 | 11.5 | 11.8 | 12.1 | 12.3 | 12.6  | 0.07 | <.0001 |
| Guillain Barré | 7.2  | 2.2  | 3.3  | 4.0  | 4.8  | 5.5  | 6.3  | 7.0  | 7.6  | 7.9  | 8.2  | 8.5  | 8.6   | 0.07 | <.0001 |
| Muscular dystrophy | 6.5  | 2.8  | 4.0  | 5.0  | 5.7  | 6.3  | 6.8  | 7.0  | 7.6  | 7.9  | 8.2  | 8.3  | 8.6   | 0.07 | <.0001 |
| Metabolic disease | 6.0  | 2.2  | 3.9  | 5.0  | 5.7  | 6.1  | 6.8  | 6.9  | 7.1  | 7.1  | 6.9  | 6.8  | 6.6   | 0.06 | <.0001 |
| NMD (non-specific) | 5.8  | 2.3  | 3.2  | 4.3  | 5.1  | 5.4  | 5.7  | 6.1  | 6.7  | 7.0  | 7.5  | 7.7  | 7.9   | 0.08 | <.0001 |
| Spina bifida | 4.6  | 1.9  | 2.7  | 3.3  | 3.9  | 4.5  | 4.9  | 5.1  | 5.5  | 5.8  | 5.9  | 6.1   | 6.0   | 0.08 | <.0001 |
| Myasthenia gravis | 0.5  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2   | 0.2   | 0.05 | <.0001 |
| ALS/MND | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | 0.00  | <.0001 |
| Post-polio syndrome | 0.4  | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.05 | 0.03 | 0.05 | 0.08 | 0.09 | 0.11 | 0.13  | 0.14 | <.0001 |
| SMA | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2   | 0.2   | 0.04  | <.0001 |

| Children |      |      |      |      |      |      |      |      |      |      |      |      |       |      |    |
|----------|------|------|------|------|------|------|------|------|------|------|------|------|-------|------|-----|
| All NMD diagnoses | 50.0 | 20.9 | 29.1 | 34.3 | 38.3 | 43.0 | 47.9 | 53.3 | 57.9 | 62.7 | 66.3 | 70.3  | 75.9  | 0.10 | <.0001 |
| Cerebral palsy | 19.5 | 11.2 | 14.5 | 16.3 | 17.7 | 18.8 | 20.1 | 20.8 | 21.6 | 22.9 | 23.5 | 24.1  | 24.1  | 0.05 | <.0001 |
| Guillain Barré | 3.4  | 0.6  | 1.0  | 1.4  | 1.7  | 2.2  | 2.9  | 3.7  | 4.3  | 4.8  | 5.4  | 5.5   | 5.6   | 0.08 | <.0001 |
| Muscular dystrophy | 3.8  | 2.4  | 2.8  | 3.1  | 3.2  | 3.7  | 4.3  | 4.4  | 4.8  | 4.9  | 5.0  | 5.6   | 0.08 | <.0001 |
| Metabolic disease | 6.3  | 2.2  | 3.5  | 4.1  | 4.5  | 5.5  | 6.0  | 6.6  | 7.3  | 7.8  | 8.6  | 9.1   | 9.9   | 0.11 | <.0001 |
| Myasthenia gravis | 0.5  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2   | 0.2   | 0.17 | <.0001 |
| ALS/MND | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | 0.12  | <.0001 |
| Spinal muscular atrophy | 0.7  | 0.4  | 0.6  | 0.7  | 0.6  | 0.6  | 0.6  | 0.7  | 0.7  | 0.8  | 0.9  | 0.7   | 0.8   | 0.04  | <.0001 |

Prevalence/100,000 individuals whose index case was identified through ED presentation or hospital admission (i.e., excludes those identified through physician billing only).

Average change in prevalence per year.
P value for linear trend.

ALS: amyotrophic lateral sclerosis; MND: motor neurone disease; NMD: neuromuscular disease (non-specific diagnosis); SMA: spinal muscular atrophy.

https://doi.org/10.1371/journal.pone.0210574.t001
Discussion

In this retrospective population based study of adults and children with NMD, we found prevalence of those requiring ED presentation or hospital admission to be increasing over time among both adults and children. Prevalence in adults is highest in the oldest age category but increased the most in the youngest age category, suggesting increased survival of children with NMD into adulthood. Overall incidence is decreasing in adults but remains static in children. Diseases for which the incidence remained unchanged in adults include neuropathies, muscular dystrophy, metabolic diseases, ALS, spina bifida and myasthenia gravis. Mortality was modest overall and has decreased over time. Two thirds of adults and 50% of children received palliative care. Receipt of palliative care has increased over time for adults and children.
Although there have been studies reporting point prevalence or birth prevalence of various forms of NMD [16, 17], none have been population-based studies in which trends in prevalence and incidence of NMD were ascertained. Prevalence is dependent on incidence and disease duration, the latter being related to disease resolution or death. Given the declining incidence in adults and static incidence in children and given that most forms of NMD do not resolve, the increasing prevalence observed can be attributed to increased survival. This is supported by the decline in crude mortality rates over the 12-year study period for both adults and children and the increased prevalence in both the youngest adult and child age categories.

The reduction in mortality found in our study is consistent with reports that identified an increased survival in various NMD populations including Duchenne Muscular Dystrophy [18], Guillain Barré syndrome [19], and ALS [20]. Reasons for this reduction are likely multifactorial. For those individuals in whom the disease progresses to respiratory failure improvements to monitoring of respiratory complications, newer technologies for lung hygiene [18].

### Table 2. Incidence by year.

|                      | Overall (yrs) | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | Rate | 95% CI   | P       |
|----------------------|---------------|------|------|------|------|------|------|------|------|---------|---------|
| **Adults**           |               |      |      |      |      |      |      |      |      |         |         |
| All NMD diagnoses    | 4.7           | 5.2  | 4.9  | 4.9  | 4.7  | 3.9  | 4.0  | 5.1  | -0.02| -0.06, 0.01| 0.1692  |
| Cerebral palsy       | 0.7           | 1.3  | 0.6  | 0.8  | 0.7  | 0.6  | 0.6  | 0.6  | -0.11| -0.2, 0.02| 0.0202  |
| Guillain Barré       | 0.5           | 0.6  | 0.7  | 0.2  | 0.3  | 0.5  | 0.4  | 0.8  | -0.03| -0.09, 0.02| 0.0047  |
| Muscular dystrophy   | 0.4           | 0.5  | 0.6  | 0.4  | 0.4  | 0.3  | 0.3  | 0.6  | -0.03| -0.07, 0.02| 0.0139  |
| Metabolic disease    | 0.7           | 0.7  | 0.6  | 0.8  | 0.5  | 0.8  | 0.6  | 0.8  | -0.02| -0.04, 0.08| 0.6077  |
| Myasthenia gravis    | <0.2          | 0.3  | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | -0.02| -0.07, 0.01| 0.0184  |
| ALS/MND              | <0.2          | 0.4  | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | -0.03| -0.07, 0.01| 0.0184  |
| Post-polio syndrome  | 0.3           | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.02| -0.04, 0.08| 0.6077  |
| SMA                  | 0.03          | 0.03 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | 0.00| -0.07, 0.02| 0.0184  |
| **Children**         |               |      |      |      |      |      |      |      |      |         |         |
| All NMD diagnoses    | 0.3           | 0.3  | 0.4  | 0.4  | 0.3  | 0.4  | 0.3  | 0.4  | 0.03| -0.11, 0.02| 0.1394  |
| Cerebral palsy       | 0.3           | 0.3  | 0.4  | 0.4  | 0.3  | 0.4  | 0.3  | 0.4  | 0.03| -0.11, 0.02| 0.1394  |
| Guillain Barré       | 0.2           | 0.2  | <0.2 | <0.2 | 0.2  | <0.2 | <0.2 | <0.2 | 0.00| -0.11, 0.02| 0.1394  |
| Muscular dystrophy   | 0.1           | 0.9  | 1.0  | 1.3  | 1.1  | 0.8  | 0.8  | 0.8  | 0.04| -0.1, 0.04| 0.0145  |
| Metabolic disease    | <0.2          | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | -0.07| -0.26, 0.12| 0.4631  |

*a* Incidence/100,000 individuals whose index case was identified through ED presentation or hospital admission (i.e., excludes those identified through physician billing only).

*b* Average change in incidence per year.

*p* P value for linear trend.

ALS: amyotrophic lateral sclerosis; MND: motor neurone disease; NMD: neuromuscular disease (non-specific diagnosis); SMA: spinal muscular atrophy.
and nocturnal ventilation [21] are likely contributors in addition to more timely access to specialist services, including multi-disciplinary and inter-professional specialist clinics [22].

Almost two thirds of adults and half the children that died received palliative care, with adult use increasing over time. Although the Canadian healthcare system offers advanced palliative care [23] most is delivered within hospitals rather than the community, with substantial variation in access to palliative care regardless of diagnosis related to geographic location [24]. Barriers to the utilization of palliative care for children and adolescents with NMD include poor family awareness of palliative care services and what they provide [25], service availability and cost, age-appropriateness of services, perceptions of palliative care and perceived benefit [26].

Fig 3. Incidence of neuromuscular disease per 100,000 adults and per 100,000 children for individuals whose index case was identified through ED presentation or hospital admission (i.e., excludes those identified through billing codes).

https://doi.org/10.1371/journal.pone.0210574.g003
Comparison with international reports of prevalence and incidence rates is challenging due to differences in case ascertainment rates and denominator. We found the prevalence of muscular dystrophy to be 8.6/100,000 adults and 5.6/100,000 children in 2014 which is lower than other international reports and likely due to restricting our estimates to those identified through hospital admission or ED presentation and therefore likely to have more severe disease. Global estimates of the prevalence of combined muscular dystrophies derived from systematic reviews of existing studies, estimate the pooled prevalence to range from 16.1/100,000 [4] to 25.1/100,000 people [16]. We observe a slightly lower prevalence (2.1/100,000 in 2014) and incidence (0.5/100,000) of ALS compared with European ALS registers (prevalence 7–9/100,000, incidence 2.6/100,000) [27]. Our observations were more in keeping with recent US estimates of ALS prevalence (4 5.0/100,000) [5].

Study limitations include the possibility of misclassification, either under or over ascertainment of NMD due to the absence of validated algorithms for case ascertainment. We restricted reporting of disease specific prevalence and incidence to those individuals identified through hospital diagnostic codes and therefore these data likely underestimate the true population rates that include mild or early disease. However, we are able to provide population-based trends in prevalence, incidence, and mortality of adults and children with NMD requiring emergent care. Coding within the health administrative database prevented more disease specific descriptions of prevalence and incidence i.e., Duchenne muscular dystrophy, the most common muscular dystrophy. We were also unable to distinguish between acute and chronic disease. Finally, delivery of palliative care may not always be coded in the health administrative databases, as some physicians may be unaware of palliative care billing codes.

Conclusion
In this population-based study of adults and children with NMD, we observed a rising prevalence of NMD, particularly in younger adults and children, whereas mortality is declining. The incidence of NMD is declining in adults with no change in children. These findings confirm on a population-based level the increased survival of children and adults with NMD, and will inform healthcare planning for NMD in the future. Although a reasonable proportion of adults and children received palliative care before death, we recommend further improvements in delivery and uptake of palliative care.

Supporting information
S1 File. Cohort creation codes and additional study data.
(DOCX)

Acknowledgments
Disclaimer: The Institute for Clinical Evaluative Sciences (ICES) is the custodian for the data used in this study. ICES is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed herein are those of the authors, and not necessarily those of CIHI.
Author Contributions

**Conceptualization:** Louise Rose, Douglas McKim, David Leasa, Mika Nonoyama, Anu Tandon, Reshma Amin, Sherri Katz, Roger Goldstein, Andrea Gershon.

**Data curation:** Louise Rose, Yu Qing Bai.

**Formal analysis:** Louise Rose, Yu Qing Bai.

**Funding acquisition:** Louise Rose.

**Methodology:** Louise Rose.

**Project administration:** Louise Rose.

**Supervision:** Andrea Gershon.

**Validation:** Louise Rose.

**Writing – original draft:** Louise Rose, Douglas McKim, David Leasa, Andrea Gershon.

**Writing – review & editing:** Louise Rose, Douglas McKim, David Leasa, Mika Nonoyama, Anu Tandon, Yu Qing Bai, Reshma Amin, Sherri Katz, Roger Goldstein, Andrea Gershon.

References

1. Korngut L, Campbell C, Johnston M, Benstead T, Genge A, Mackenzie A, et al. The CNDR: collaborating to translate new therapies for Canadians. Can J Neurol Sci. 2013; 40:698–704. PMID: 23968944

2. Howard R. Respiratory failure because of neuromuscular disease. Curr Opin Neurol. 2016; 29:592–601. https://doi.org/10.1097/WCO.0000000000000363 PMID: 27427990

3. Bray G, Strachan D, Tomlinson M, Bienek A, Pelletier C. Mapping Connections: an understanding of neurological conditions in Canada. Ottawa: Public Health Agency of Canada, 2014.

4. Mah J, Korngut L, Fiest K, Dykeman J, Day L, Pringsheim T, et al. A systematic review and meta-analysis on the epidemiology of the Muscular Dystrophies. Can J Neurol Sci. 2016; 43:163–77. https://doi.org/10.1017/cjn.2015.311 PMID: 26786644

5. Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of Amyotrophic Lateral Sclerosis—United States, 2012–2013. MMWR Surveill Summ. 2016; 65:1–13.

6. Mah J, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014 24:482–91 https://doi.org/10.1016/j.nmd.2014.03.008 PMID: 24780148

7. Statistics Canada. 2011 Census profile Ottawa: Government of Canada; 2013 [accessed 28th Nov 2017]. http://www12.statcan.gc.ca/census-recensement/index-eng.cfm.

8. Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: A validation study. Toronto: Institute for Clinical Evaluative Sciences, 2006.

9. Herring A, Ginde A, Fahimi J, Alter H, Maselli J, Espinola J, et al. Increasing critical care admissions from U.S. emergency departments, 2001–2009. Crit Care Med. 2013; 41:1197–204. https://doi.org/10.1097/CCM.0b013e31827c0861

10. Tanuseputro P, Budhwan S, Bai Y, Wodchis W. Palliative care delivery across health sectors: A population-level observational study. Palliat Med. 2016; 31:247–57. https://doi.org/10.1177/0269216316653524 PMID: 27317412

11. Ray J, Redelmeier D, Urquia M, Guttmann A, McDonald S, Vermeulen M. Risk of cerebral palsy among the offspring of immigrants. PLoS One. 2014; 9:e102275. https://doi.org/10.1371/journal.pone.0102275 PMID: 25019202

12. Breiner A, Widdifield J, Katzberg H, Barnett C, Bril V, K T. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016; 26:41–6. https://doi.org/10.1016/j.nmd.2015.10.009 PMID: 26573434

13. Widdifield J, Ivers N, Young J, Green D, Jaakkimainen L, Butt D, et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. Mult Scler. 2015; 21:1045–54. https://doi.org/10.1177/1352458514556303 PMID: 25992338
14. Kwong J, Vasa P, Campitelli M, Hawken S, Wilson K, Rosella L, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis. 2013; 13:769–76. https://doi.org/10.1016/S1473-3099(13)70104-X

15. UCLA: Statistical Consulting Group. SAS Code Fragments: Analyzing changes in trend over time Los Angeles: UCLA; [18th Dec 2018]. https://stats.idre.ucla.edu/sas/code/analyzing-changes-in-trend-over-time/.

16. Theadom A, Rodrigues M, Roxburgh R, Balalai S, Higgins C, Bhattacharjee R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014; 43:259–68. https://doi.org/10.1159/000369343 PMID: 25532075

17. Ryder S, Leadley R, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017; 12:79. https://doi.org/10.1186/s13023-017-0631-3 PMID: 28446219

18. Kiency P, Chollet S, Delalande P, Le Fort M, Magot A, Peron Y, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013; 56:443–54. https://doi.org/10.1016/j.rehab.2013.06.002 PMID: 23876223

19. Ruiz E, Ramalle-Gómez E, Quiñones C, Martinez-Ochoa E. Trends in Guillian-Barré syndrome mortality in Spain from 1999 to 2013. Int J Neurosci. 2016; 126:985–8. https://doi.org/10.3109/00207454.2015.1090437

20. Mehul J, Holman R, Schonberger L, Sejvar J. Amyotrophic lateral sclerosis/motor neuron disease deaths in the United States, 1999–2009. Amyotrophic Lateral Sclerosis Frontotemporal Degener 2013; 14:346–52. https://doi.org/10.3109/21678421.2013.787629

21. Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, et al. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuro-muscul Disord. 2007; 17:470–5. https://doi.org/10.1016/j.nmd.2007.03.002

22. Traynor B, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003; 74:1258–61. https://doi.org/10.1136/jnnp.74.9.1258

23. Connor S, Sepulveda Bermedo M. Global atlas of palliative care at the end of life. London: Worldwide Palliative Care Alliance, 2014.

24. Hsu A, Tanuseputro P. The delivery of palliative and end-of-life care in Ontario. Healthc Q. 2017; 20:6–9.

25. Arias R, Andrews J, Pandya S, Pettit K, Trout C, Apkon S, et al. Palliative care services in families of males with Duchenne muscular dystrophy. Muscle Nerve. 2011; 44:93–101. https://doi.org/10.1002/mus.22005 PMID: 21674523

26. Parker D, Maddocks I, Stern L. The role of palliative care in advanced muscular dystrophy and spinal muscular atrophy. J Paediatr Child Health. 1999; 35:245–50. PMID: 10404443

27. Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg L, Chio A, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017; 88.